Page last updated: 2024-08-20

dextrothyroxine and 2019 Novel Coronavirus Disease

dextrothyroxine has been researched along with 2019 Novel Coronavirus Disease in 215 studies

Research

Studies (215)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	215 (100.00)	2.80

Authors

Authors	Studies
Bryant, A; Fordham, EJ; Lawrie, TA	1
Bhatnagar, S; Bhopale, S; Boppana, TK; Das, US; Dwivedi, T; Garg, R; Guleria, R; Gupta, N; Gupta, R; Hadda, V; Jain, A; Madan, K; Mahajan, S; Masih, S; Meena, VP; Mittal, S; Mohan, A; Pandey, RM; Pandit, A; Patel, A; Sahoo, B; Shelke, SS; Singh, AR; Suri, TM; Tiwari, P; Velpandian, T; Vig, S	1
Ahmad, A; Akmal, R; Akram, MK; Alahmadi, YM; Arshad, S; Ashraf, M; Ashraf, S; Awais, AB; Farooq, I; Ghufran, M; Gul, M; Habib, Z; Hassan, M; Humayun, A; Imran, MA; Izhar, M; Kalsoom, L; Khalid, H; Majeed, N; Munir, I; Munir, K; Rafique, S; Saboor, QA; Safdar, Z; Sherazi, SSH; Siddiqui, UN; Virk, MAR	1
Barreiro, F; Barrenechea, G; Chahla, RE; D' Amato Rn, S; George, A; Goroso, DG; Mancilla Rn, C; Medina Ruiz, L; Morales Rn, MF; Ortega, ES; Peral de Bruno, M	1
Chaudhry, MW; Irfan, M; Zubair, SM; Zubairi, ABS	1
Cobucci, RN; Linhares, PVA; Machado, MLL; Martins Ferreira, CF; Martins, RR; Oliveira Silva, DF; Souza, ATB	1
Ali, S; Deng, J; Heybati, K; Hou, W; Huang, E; Wong, CY; Zhou, F	1
Barkati, S; Greenaway, C; Libman, MD	1
Broderick, N; Byrne, P; Cardwell, K; Harrington, P; O Murchu, E; O'Neill, M; O'Neill, SM; Ryan, M; Smith, SM; Walsh, KA	1
Apperloo, L; Bouma, EM; Carpaij, OA; Dinesh Kumar, N; Nawijn, MC; Rodenhuis-Zybert, IA; Smit, JM; Stienstra, Y; Ter Ellen, BM; Troost, B; van de Pol, DPI; van den Berge, M; van der Ende-Metselaar, HH; van Gosliga, D	1
Nogrady, B	1
Hendrickson, RG; Hoang, R; Temple, C	1
Lal, SK; Low, ZY; Yip, AJW	1
Tsanni, A	1
Scialli, AR; Wise, LD	1
Anandakrishnan, R; Balderas, RM; Conception, R; Effendi, M; Goksu, SY; Gugnani, M; Mahdi, M; Manning, Z; Ozer, M; To, K; Ulker, E; Whitman, M	1
Mathachan, SR; Sardana, K	1
Acierno, S; Ametrano, O; Angrisani, F; Barbato, F; D'Anna, C; Di Mita, O; Esposito, S; Giannattasio, A; Rosa, M; Tipo, V	1
Bardoulat, I; Blanchon, T; Fardet, L; Launay, T; Lemaitre, M	1
Echeverría-Esnal, D; Grau, S	1
Barneck, MD; Giordano, PA; Rothrock, SG; Weber, KD	2
Alvisi, MF; Antinori, S; Bisoffi, Z; Buonfrate, D; Campoli, C; Casalini, G; Chesini, F; De Simone, I; Deiana, M; Gobbi, M; Lunardi, G; Martini, D; Nobili, A; Ojeda Fernandez, ML; Pomari, E; Roncaglioni, MC; Rulli, E; Tessari, R	1
Calello, DP; Kazzi, Z; Stolbach, A	1
Fujino, Y; Hirata, H; Kabata, D; Koide, M; Ogura, H; Shimizu, K; Shintani, A; Tachino, J; Tokuhira, N; Uchiyama, A; Ueda, A	1
Watson, C	1
Dauby, N; Hites, M; Taccone, FS	1
Ab Wahab, S; An, N; Cheah, WK; Cheng, JT; Chidambaram, SK; Chow, TS; Hor, CP; Ker, HB; Khalid, KE; Khoo, SWR; King, TL; Koh, HM; Lai, NM; Lim, HH; Lim, SCL; Loh, JH; Low, LL; Mat Jelani, A; Mohd Unit, H; Nasruddin, AB; Peariasamy, KM; Song, LH; Tan, WH; Tay, KH; Zaid, M; Zaidan, NZ	1
Chen, H; Doud, EH; Guo, S; Han, L; Liu, J; Rubart-von der Lohe, M; Wan, J; Wang, C; Wu, S; Yang, L; Zhang, Y	1
Boretti, A	1
Griffin, LR; Laing, ME; Markham, T; Pender, EK	1
Kieliszek, M	1
Bitterman, A; Cices, A; Martins, CP; Nadendla, MP	1
Tedeschi, S; Ventura, L	1
Bisoffi, Z; Buonfrate, D; Rulli, E	1
Medina Arellano, MJ; Meyerowitz-Katz, G; Wieten, S; Yamey, G	1
Akaslan, TÇ; Mert, Ö; Su Küçük, Ö	1
Alam, P; Alanazi, A; Alhazmi, BH; Alrashdi, BA; Alrasheedi, NS; Alshammari, MK; Alyami, SS; Arora, MK; Asdaq, SMB; Bhatt, P; Imran, M; Sharma, P; Sharma, SK; Tomar, R	1
Duverger, E; Herlem, G; Picaud, F	1
Bomze, D; Geller, S; Sprecher, E	1
Aldy, K; Brent, J; Burkhart, K; Farah, R; Kazzi, Z; Wax, P	1
Atmakuri, S; Khatri, D; Nene, S; Singh, SB; Sinha, VR; Srivastava, S	1
Alvarado, YJ; González-Paz, L; Hurtado-León, ML; Jeffreys, LN; Loroño, M; Lossada, C; Olivarez, Y; Paz, JL; Torres, FJ; Vera, E; Vera-Villalobos, J; Vivas, A	1
Asaduzzaman, M; Islam, ABMMK; Morshed, N; Reza, R; Samdani, MN	1
Elliott, JH; Henry, D; Pearson, SA; Schaffer, AL; Zoega, H	1
Hausinger, RI; Kranke, P; Metzendorf, MI; Meybohm, P; Popp, M; Reis, S; Schießer, S; Skoetz, N; Stegemann, M; Weibel, S	1
Amos, J; Annie, FH; Campbell, J; Searls, L	1
Ccami-Bernal, F; Coba-Villan, N; Fernandez-Guzman, D; Grados-Espinoza, P; Morocho-Alburqueque, N; Nieto-Gutierrez, W; Quispe-Vicuña, C; Sangster-Carrasco, L; Soriano-Moreno, DR; Velasquez-Fernandez, R	1
Bonanno, M; Lee, OS; Sayed, C	1
Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE	1
Ocanha-Xavier, JP; Xavier-Junior, JCC	1
Maneerit, J; Manomaipiboon, A; Pholtawornkulchai, K; Phumisantiphong, U; Poopipatpab, S; Ruksakul, W; Suraamornkul, S; Trakarnvanich, T	1
Anderson, B; Avula, N; Belani, HK; Biros, M; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Fricton, R; Hagen, AA; Hartman, KM; Huling, JD; Ingraham, NE; Karger, AB; Klatt, NR; Lee, S; Liebovitz, DM; Lindberg, S; Luke, DG; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, MF; Puskarich, MA; Rao, V; Reddy, NV; Saveraid, HG; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Tordsen, WJ; Zaman, A	1
Apodaca Michel, B; Du Plessis, JD; Gagyor, I; Gunesch, C; Kasang, C; Navarro, M; Parisi, S; Pritsch, M; Rubilar, G; Saavedra Irala, C; Schrader, H; Schwienhorst-Stich, EM; Shock, J; Zirkel, J; Zoller, T	1
Borody, TJ; Dave, S; Hazan, S; McCullough, PA	1
Correa, MB; Demarco, FF; Lima, GS; Martins-Filho, PR; Moraes, RR	1
Alsmadi, MM	1
Balme, K; Decloedt, EH; Du Plessis, CE; Marks, CJ; Pillay-Fuentes Lorente, V; Reuter, H; Stephen, C; Van Rensburg, R; Voigt, G	1
Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G	1
Adam, SJ; Boulware, DR; Bramante, CT; Castro, M; Collins, S; DeLong, A; Dunsmore, SE; Felker, GM; Gabriel, A; Gentile, N; Ginde, AA; Hanna, G; Hernandez, AF; Jayaweera, D; Lenert, LA; Lindsell, CJ; McCarthy, MW; McTigue, K; Naggie, S; Remaly, A; Shah, NS; Shenkman, E; Slandzicki, AJ; Stewart, TG; Sulkowski, M; Thicklin, F; Wilder, R; Wilson, S	1
Shibuya, K; Taniguchi, K; Tokuda, Y; Watari, T	1
Clemons, J; Correia, MS; Hendrickson, RG; Hoang, R; Temple, C	1
Gomes, T; Ho, M; Iacono, A; Suda, K; Tadrous, M	1
Hu, GY; Liang, CA; Lin, CY; Lin, PC	1
Cid-López, MA; de la Rocha, C; Gómez-Méndez, SC; Gutiérrez-Dieck, GA; Hernández-Puente, CV; Iglesias-Palomares, C; Llamas-Velázquez, RA; Luna-Gudiño, N; Méndez-Del Villar, M; Mercado-Cerda, J; Mercado-Sesma, AR; Meza-Acuña, AI; Milenkovic, J; Pérez-Ríos, AM; Robles-Bojórquez, JG; Rosales-Galván, D; Sánchez-Ortiz, A; Tavares-Váldez, A; Valderrábano-Roldán, CG; Vargas-Íñiguez, B; Venegas-López, BI	1
Misra, S; Shukla, AK	2
Boulware, DR; Bramante, CT; Buse, JB	1
Furlan, L	1
Jimenez, CA; Mejía, JH	1
Mills, EJ; Reis, G	1
Barus, R; Gautier, S; Wabont, G	1
Alibudbud, R	1
Barbuto, AF; Burns, MM; Chary, MA; Fleischer, E; Izadmehr, S; Tarsillo, M	1
Ostrovsky, AM; Parikh, C	1
Quail, MT	1
Hill, A; Mirchandani, M	1
Akbari, A; Aziziyan, F; Bahreini, E; Effatpanah, H; Moeini, AM; Mohebi, F; Moradi-Sardareh, H; Nabi-Afjadi, M; Zalpoor, H	1
Löscher, W	1
Harada, KH; Phosri, A	1
Kubiska, M; Šín, R	1
Becker, NV; Chua, KP; Conti, RM; Echevarria, K; Prescott, HC; Seelye, S	1
Bukowski, LA; Kahn, JM; Levin, JM; Minson, JA	1
Abdad, MY; Blacksell, S; Boyd, S; Callery, JJ; Chotivanich, K; Chotivanich, V; Cruz, C; Day, NPJ; Dondorp, AM; Ekkapongpisit, M; Hanboonkunupakarn, B; Hanboonkunupakarn, P; Imwong, M; Jittamala, P; Kruabkontho, V; Luvira, V; Ngamprasertchai, T; Ngernseng, T; Phumratanaprapin, W; Piaraksa, N; Piyaphanee, W; Pongwilai, S; Poovorawan, K; Pukrittayakamee, S; Ruksakul, W; Sangketchon, C; Schilling, WHK; Siripoon, T; Sookprome, S; Suwannasin, K; Tarning, J; Taylor, WRJ; Teixeira, MM; Thaipadungpanit, J; Tubprasert, J; Watson, JA; White, NJ	1
Bibbins-Domingo, K; Malani, PN	1
London, AJ; Seymour, CW	1
Adam, SJ; Amon, AP; Boulware, DR; Castro, M; Cohen, J; Collins, S; DeLong, A; Dunsmore, SE; Felker, GM; Gabriel, A; Gentile, N; Ginde, AA; Hanna, GJ; Hernandez, AF; Jayaweera, D; Kavtaradze, D; Lim, SC; Lindsell, CJ; McCarthy, MW; McTigue, K; Naggie, S; Remaly, A; Rothman, RL; Shenkman, E; Slandzicki, AJ; Stewart, TG; Sulkowski, M; Thicklin, F; Wilder, R; Wilson, S	1
Bella, Z; Csupor, D; Dembrovszky, F; Farkas, N; Hegedüs, I; Hegyi, P; Kiss, S; Máthé, D; Matuz, M; Ragó, Z; Szalenko-Tőkés, Á; Tóth, B; Tóth, N	1
Aleksić, MM; Ivković, B; Kotur-Stevuljević, J; Rupar, J; Selaković, M	1
Andrews, R; Boara, D; Engelman, D; Gorae, C; Grobler, AC; Kaldor, JM; Lake, SJ; Marks, M; Nasi, T; Osti, MH; Parnaby, M; Phelan, S; Romani, L; Schuster, T; Sokana, O; Steer, AC; Whitfeld, MJ; Zinihite, J	1
Bopda, J; Dongmo-Yemele, R; Efon-Ekangouo, A; Geiger, A; Kamgno, J; Nana-Djeunga, HC; Nutman, TB; Nzune-Toche, N; Ongbassomben, V; Sumo, L	1
Astărăstoae, V; Rogozea, LM	1
Giarolla, J; Parise-Filho, R; Polli, MC; Vassiliades, SV; Vaz, ES	1
Andrade, ACS; Muraro, AP; Rocha, RPDS; Silva, NBLD; Terças-Trettel, ACP	1
Hanaki, H; Kobayashi, N; Matsui, H; Ōmura, S; Takano, T; Uematsu, T	1
Mino-León, D; Requejo Domínguez, JA; Wirtz, VJ	1
Borrajo Brunete, E; Del Pozo, A; Devesa García, C; González Cuello, I; Llenas-García, J; Lucas Dato, A; Navarro, M; Poveda Ruiz, N; Roig-Sánchez, N; Talaya, A; Wikman-Jorgensen, P	1
Mudini, W; Sonderup, M; Spearman, W	1
Manu, P	1
Anderson, BJ; Beckman, KB; Belani, HK; Bhat, NS; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Griffiths, G; Hartman, KM; Huling, JD; Karger, AB; Klatt, NR; Liebovitz, DM; Lindberg, SM; Mehta, T; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, M; Puskarich, MA; Rose, MR; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Wirtz, EL	1
Breitinger, HG; Breitinger, U; Sedky, CA; Sticht, H	1
Aminpour, M; Santin, AD; Scheim, DE; Tavernini, S; Tuszynski, JA; Vottero, P	1
Díaz, S; Durán-Álvarez, JC; Prado, B; Rodríguez, M; Zanella, R	1
Azimi, A; Davoodi, L; Fakhar, M; Khorshidvand, Z; Mirbadiei, SR; Mizani, A; Parandin, F; Shayesteh Azar, S; Soleymani, E	1
de Oliveira, AHP; Dotto, GL; Franco, DSP; Georgin, J; Mallmann, ES; Netto, MS; Pinto, D; Silva, LFO	1
Ayong, L; Ghogomu, SM; Ngwese, RA; Njemini, R; Shey, RA; Shintouo, CM; Souopgui, J; Teh, RN; Vanhamme, L; Yaah, NE; Yengo, BN	1
Barbosa, AN; Bernardo, WM; Chebabo, A; Cimerman, S; Croda, J; Cunha, CA; de Luna, D; Falavigna, M; Ferreira, JC; Gomes-da-Silva, MM; Nunes, EP; Parahiba, SM; Pérez, C; Rodriguez-Morales, AJ; Starling, C; Tanni, S; Thormann, M; Zambrano, G	1
Bijlsma, MJ; de Vos, S; Hak, E; Mol, P; Niesters, HGM; Oude Rengerink, K; Pasmooij, AMG; van Baarle, D; Verweij, S; Vonk, JM; Zhou, G	1
Lai, C; Toriumi, F; Yoshida, M	1
Ahiskali, A; Shaughnessy, M; Swart, B; Wolf, JM	1
Ahamadi, A; Asgary, A; Bragazzi, NL; Kong, JD; Mellado, B; Movahedi Nia, Z; Orbinski, J; Seyyed-Kalantari, L; Woldegerima, WA; Wu, J	1
Hu, X; Jiao, X; Li, K; Li, L; Li, M; Lu, Y; Meng, F; Zhang, M	1
Druckman, JN; Green, J; Lazer, D; Lunz Trujillo, K; Ognyanova, K; Perlis, RH; Safarpour, A; Santillana, M	1
Aseffa, A; Behaksira, S; Debebe, K; Gadisa, E; Gebre, T; Geleta, D; Gemechu, L; Kebede, B; Kebede, F; Mabey, DCW; Mammo, B; Marks, M; McPherson, S; Miecha, H; Oljira, B; Seife, F; Solomon, AW; Solomon, H; Tadesse, F; Tafese, G; Tafese, T	1
Ilona Hausinger, R; Kranke, P; Metzendorf, MI; Meybohm, P; Popp, M; Reis, S; Schießer, S; Skoetz, N; Stegemann, M; Weibel, S	1
Marko, M; Pawliczak, R	1
Singh, S; Yang, YF	1
Campi-Caballero, R; Correa-Basurto, J; Espinosa-Raya, J; García-Aguilar, A; García-Machorro, J; García-Sánchez, JR; Visoso-Carvajal, G	1
Caly, L; Catton, MG; Druce, JD; Jans, DA; Wagstaff, KM	1
Fabbrocini, G; Patrì, A	1
Şimşek Yavuz, S; Ünal, S	1
Chaccour, C; Hammann, F; Rabinovich, NR; Ramón-García, S	1
Bray, M; Jans, D; Noël, F; Rayner, C; Wagstaff, K	1
Tapia, L	1
Anastasiou, IA; Eleftheriadou, I; Tentolouris, A; Tentolouris, N; Tsilingiris, D	1
Hajlaoui, K; Karray, M; Litaiem, N; Slouma, M; Zeglaoui, F	1
Wamae, CN	1
Rizzo, E	1
Bonilla-Aldana, DK; Dhama, K; Leblebicioglu, H; Patel, SK; Pathak, M; Rodriguez-Morales, AJ; Sah, R; Sharun, K; Singh, BR; Tiwari, R	1
Azanza, JR; Brew, J; Carmona-Torre, F; Casellas, A; Chaccour, C; Dobaño, C; Fernández, M; Giráldez, M; Hammann, F; Moncunill, G; Mota, JS; Rabinovich, R; Reina, G; Richardson, MA; Ruiz-Castillo, P; Sadaba, B; Yuste, JR	1
Freeman, PR; Horowitz, RI	1
Ahmed, SN; Banerjee, K; Dalai, CK; Nandy, M	1
Burger, JA; de Castro, CG; Gregianin, LJ	1
Allouche, M; Alwasel, S; Beyrem, H; Boufahja, F; Essid, N; Harrath, AH; Lazzem, M; Mahmoudi, E; Mansour, L	1
Alvarez, RA; Auerbach, JS; de Marchena, EJ; Delazerda, D; Ghodsizad, A; Grant, AA; Guerra, G; Hare, J; Khalid, L; Loebe, M; Mirsaeidi, M; Sneij, WC; Vianna, R	1
Alonso, DF; Farina, HG	1
Alarcon, S; Chávez, S; Díaz, R; García, J; Gutierrez, C; Hernandez, E; León, E; Maradiegue, E; Maza, I; Montoya, J; Moore, C; Morales, R; Ordoñez, K; Reaño, R; Rojas, N; Sanchez, K; Ugaz, C; Valdiviezo, C; Vargas, MP; Vásquez, L; Zapata, A	1
Arora, VK; Behera, D; Tripathy, SK; Vora, A	1
Cao, Y; Hanafin, PO; Jermain, B; Lanusse, C; Lifschitz, A; Rao, GG	1
Barroso, J; DiNicolantonio, JJ; McCarty, M	1
Castelli, F; Castelnuovo, F; Cristini, G; Crosato, V; Gulletta, M; Marchese, V; Matteelli, A	1
Jans, DA; Wagstaff, KM	1
Hasan, M; Hasan, MN; Hosen, MJ; Jaman, J; Karim, MA; Karim, Z; Parvez, MSA; Tahsin, T	1
Gupta, SP	1
Perišić, O	1
González-Cuevas, R; Ortega-Peña, M	1
Azañedo, D; Hernández-Vásquez, A; Vargas-Fernández, R	1
Abizanda, G; Aldaz, A; Casellas, A; Chaccour, C; Gil, AG; Hammann, F; Irigoyen-Barrio, Á; Martínez-Galán, F	1
Fatteh, N; Rajter, JC; Rajter, JJ; Sacks, J; Sherman, MS; Vogel, F	1
Mega, ER	1
Almuedo-Riera, A; Camprubí, D; Grau-Pujol, B; Hurtado, JC; Krolewiecki, A; Martí-Soler, H; Muñoz, J; Soriano, A; Subirà, C	1
Das, S; Meher, BR; Mohanty, RR; Padhy, BM	1
Achinelli, F; Aguirre, MG; Andino, G; Aquino, A; Bangher, M; Bobadilla, A; Campias, C; Chaparro Campias, E; Dellamea, S; Farizano Salazar, D; Flores, V; Guglielmone, HA; Kawerin, P; Martemucci, CN; Martinez, SM; Medina, F; Meza, E; Ojeda, J; Plano, F; Ruiz Diaz, NE; Segovia, JE; Vallejos, J; Vernengo, MM; Villamandos, S; Zoni, R	1
Goodridge, A; Torres-Atencio, I; Vega, S	1
Mittal, N; Mittal, R	1
Mishra, SK; Tripathi, T	1
Hellwig, MD; Maia, A	1
Ahmed, S; Aziz, AB; Clemens, JD; Hasnat, MA; Hossain, MS; Kabir, A; Karim, MM; Khan, WA; Phru, CS; Rahman, M; Ross, AG; Somani, J; Sumiya, MK; Yasmin, R; Zaman, K	1
Iseki, K; Kanemitsu, K; Kawamata, T; Kitakawa, K; Minemura, H; Morimoto, J; Naito, S; Nakamura, K; Nikaido, T; Onuma, T; Rikimaru, M; Sato, Y; Shibata, Y; Suzuki, Y; Takiguchi, Y; Tanino, Y; Togawa, R; Tomita, H; Tsukada, Y; Uematsu, M; Umeda, T	1
Kumar, D; Trivedi, N; Verma, A	1
de Carvalho, JF	1
Dadvand, H; Davoodian, P; Fathalipour, M; Ghazizadeh, S; Hassaniazad, M; Hassanipour, S; Hosseini, FS; Kahoori, S; Malektojari, A; Nikoofal-Sahlabadi, S; Nikpoor, AR; Sepandi, M	1
Wen, S; Xu, X; Yadav, AK; Yu, L	1
Devi, S; Kar, N; Mohakud, S; Muthuvel, D	1
Ahmed-Belkacem, A; Bernigaud, C; Berry, F; Chenost, C; Chosidow, O; Do-Pham, G; Fourati, S; Giraudeau, B; Grimaldi-Bensouda, L; Guillemot, D; Lespine, A; Softic, L	1
Domb, AJ; Neuberger, A; Petersiel, N; Rakedzon, S; Schwartz, E	1
Alvarez, L; Ballent, M; Ceballos, L; Daniele, M; Errecalde, F; Errecalde, J; Gold, S; Krolewiecki, A; Lanusse, C; Lifschitz, A; Marín, G; Spitzer, E; Toneguzzo, F; Turic, E; Vecchioli, G	1
Arouche, TDS; Costa, FLP; Filho, TSA; Júnior, RNC; Martins, AY; Neto, AMJC; Ramalho, TC	1
Basáñez, MG; Blok, DJ; de Vlas, SJ; Downs, P; Hamill, LC; Hamley, JID; Hopkins, AD; Milton, P; Stolk, WA; Walker, M	1
Bal, SK; Batmanabane, G; Behera, P; Chandanshive, PD; Mohanty, RR; Mohapatra, PR; Padhy, BM; Patro, BK; Pentapati, SSK; Pradhan, SK; S R, R; Singh, AK; Singh, SR	1
Ademuyiwa, AO; Adeyemo, WL; Ajayi, AA; Akase, IE; Alakaloko, FM; Babalola, OE; Bode, CO; Omilabu, S; Otrofanowei, E; Salu, OB	1
Araújo, AMM; Araújo, JV; Asato, MS; Buttenbender, SF; Carbonell, RCC; da Fonseca, AJ; Da Rocha, JG; de Andrade, SB; de Lima Moreira, A; de Sousa Resende, J; de Souza, RGS; Galan, LEB; Marques, FSS; Paiva, ADP; Portella, DGS; Santos, NMD; Santos, PL; Silva, GMA; Tizolim, MR	1
Hasan, SS; Kow, CS; Merchant, HA; Mustafa, ZU	1
Hastings, R; Jha, R; Kumar, P; Quek, E; Tahir, H	1
Ardila, EKG; Bravo, LE; Guerrero, E; Guerrero, R; Muñoz, E	1
Carcamo, CP; Chaccour, C; Garcia, PJ; Leon, P; Malaga, G; Mundaca, H; Ugarte-Gil, C	1
Bello, M	1
Barroso-Aranda, J; DiNicolantonio, JJ; McCarty, MF	1
Garegnani, LI; Madrid, E; Meza, N	1
Gonçalves, MVM; Nakaya, HI; Peron, JPS; Schlindwein, MAM	1
Agarwal, A; Agoritsas, T; Azab, M; Bartoszko, JJ; Brignardello-Petersen, R; Chu, DK; Couban, R; Devji, T; Foroutan, F; Ghadimi, M; Guyatt, GH; Honarmand, K; Ibrahim, S; Izcovich, A; Khamis, A; Kum, E; Lamontagne, F; Loeb, M; Martinez, JPD; McLeod, SL; Motaghi, S; Murthy, S; Mustafa, RA; Qasim, A; Rochwerg, B; Roldan, Y; Siemieniuk, RAC; Soto, GB; Switzer, C; Thabane, L; Vandvik, PO; Vernooij, RWM; Wang, Y; Yao, L; Zeraatkar, D	1
Decloedt, EH; Lahri, S; Parker, A; Reuter, H; Schrueder, N; Van Rensburg, R	1
Bhorat, AE; Bhorat, QE	1
Avcı, İY; Çetinkaya, RA; Demirtürk, N; Eser, F; Güner, R; Karalezli, A; Kayaaslan, B; Konya, P; Okumuş, N; Orhan, S; Savaşçı, Ü; Şaylan, B; Taşkın, G; Yamanel, L; Yılmaz, G	1
Coila, E; Meneses, G; Ortega-Guillén, E	1
Bisoffi, Z; Buonfrate, D	1
Rajter, JC; Rajter, JJ; Sherman, M	1
Ahmed, KGU; Alam, I; Barshan, AD; Hoque, MM; Hossain, MZ; Islam, MM; Islam, MS; Kabir, AKMH; Mahmud, R; Mallik, MU; Monayem, FB; Rahman, MM; Rassel, MA; Sayeed, SKJB; Yusuf, MA	1
Akbar, SMF; Debnath, CR; Khan, MSI; Mahtab, MA; Matsuda, S; Nabeka, H; Nath, PN	1
Meylan, P	1
Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D	1
Davoudi, A; Eslami, G; Hosseinzadeh, F; Markowitz, JS; Movahedi, FS; Navaeifar, MR; Rezai, MS; Shahbaznejad, L	2
Al-Wakeel, M; Alsaabi, A; Ayoub, H; Bazzal, AA; Chouman, M; Eid, AH; Fawaz, M; Hajjeh, O; Hassan, H; Mouawia, H; Moussawi, MA; Raad, A; Raad, H; Saab, HB; Salami, A; Samaha, AA	1
Abd El Ghafar, MS; Abd-Elsalam, S; Alboraie, M; Badawi, R; Cordie, A; Elbahnasawy, M; Eldeen, MAS; Esmail, ES; Esmat, G; Hassany, SM; Khalaf, M; Medhat, MA; Moustafa, EF; Noor, RA; Ramadan, HK; Soliman, S	1
Bryant, A; Dowswell, T; Fordham, EJ; Hill, SR; Lawrie, TA; Mitchell, S; Tham, TC	1
Byrne, P; Harrington, P; O Murchu, E; O'Neill, M; Ryan, M; Spillane, S	1
Abdelmaksoud, AA; Aref, ZF; Bazeed, SEES; Hassan, AS; Hassan, MH; Hassan, RG; Rashad, A	1
Bourhy, H; Changeux, JP; Cokelaer, T; de Melo, GD; Feige, L; Hardy, D; Kergoat, L; Kornobis, E; Larrous, F; Lazarini, F; Lecuit, M; Levallois, S; Lledo, PM; Marchio, A; Pineau, P	1
Misra, DS; Shukla, DAK	1
Achinelli, F; Aguirre, MG; Andino, G; Aquino, AC; Bangher, M; Bobadilla, A; Campias, C; Chaparro Campias, E; Dellamea, S; Farizano Salazar, D; Flores, V; Guarrochena, JM; Guglielmone, HA; Kawerin, P; Martemucci, CN; Martinez, SM; Medina, MF; Meza, E; Ojeda, J; Plano, F; Reynoso, PI; Robledo, ME; Ruiz Diaz, N; Segovia, JE; Sosa, NC; Vallejos, J; Vernengo, MM; Villamandos, S; Zoni, R	1
Adeniye, L; Bella, R; Fittler, A; Katz, Z	1
Gould, S; Kranke, P; Metzendorf, MI; Meybohm, P; Popp, M; Skoetz, N; Stegemann, M; Weibel, S	1
Ahmed, S; Khan, WA	1
Adelusi, TI; Chowdhury, A; Gao, Y; Jahan, N; Maitra, P; Sajid, M; Wang, S; Wu, X; Yin, G	1
Reardon, S	1
Burela, PA; Hernandez, AV; Pasupuleti, V; Piscoya, A; Roman, YM; Vidal, JE	1
Hagiya, H; Otsuka, F	1
Iglesias, J; Kory, P; Marik, PE; Meduri, GU; Varon, J	1
Hasan, SS; Kow, CS	1
Kranke, P; Metzendorf, MI; Meybohm, P; Popp, M; Skoetz, N; Stegemann, MS; Weibel, S	1
Apiñaniz, A; Cobos-Campos, R; Cordero, J; García, S; Orruño, E; Parraza, N	1
Alvarado, YJ; Fernández-Materán, FV; González-Paz, L; Hurtado-León, ML; Jeffreys, L; Loroño, M; Lossada, C; Paz, JL; Vera-Villalobos, J	1

Reviews

42 review(s) available for dextrothyroxine and 2019 Novel Coronavirus Disease

Article	Year
Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature. Advances in respiratory medicine, 2021, Volume: 89, Issue:4 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; Length of Stay	2021
Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM : monthly journal of the Association of Physicians, 2021, Dec-20, Volume: 114, Issue:10 Topics: COVID-19; Hospitalization; Humans; Ivermectin; Observational Studies as Topic; Respiration, Artificial; SARS-CoV-2	2021
Pharmacological interventions to prevent Covid-19 disease: A rapid review. Reviews in medical virology, 2022, Volume: 32, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; SARS-CoV-2	2022
Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. Biochimica et biophysica acta. Molecular basis of disease, 2022, 02-01, Volume: 1868, Issue:2 Topics: Animals; Antiparasitic Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Repositioning; Humans; Ivermectin; Karyopherins; SARS-CoV-2; Virus Replication	2022
Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2022, Volume: 71 Topics: Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ivermectin; SARS-CoV-2; Treatment Outcome; Zinc	2022
Selenium in the Prevention of SARS-CoV-2 and Other Viruses. Biological trace element research, 2023, Volume: 201, Issue:2 Topics: COVID-19; Humans; Hydroxychloroquine; Ivermectin; SARS-CoV-2; Selenium	2023
Comparison of Trials Using Ivermectin for COVID-19 Between Regions With High and Low Prevalence of Strongyloidiasis: A Meta-analysis. JAMA network open, 2022, 03-01, Volume: 5, Issue:3 Topics: Antiparasitic Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Endemic Diseases; Humans; Ivermectin; Prevalence; Randomized Controlled Trials as Topic; Risk; Strongyloidiasis	2022
Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review. Journal of infection and public health, 2022, Volume: 15, Issue:5 Topics: COVID-19; Cytokine Release Syndrome; Doxycycline; Humans; Ivermectin; SARS-CoV-2; Vaccination	2022
Forging Ahead the Repositioning of Multitargeted Drug Ivermectin. Current drug delivery, 2023, Volume: 20, Issue:8 Topics: COVID-19; Drug Repositioning; Humans; Ivermectin; Onchocerciasis; SARS-CoV-2	2023
Ivermectin for preventing and treating COVID-19. The Cochrane database of systematic reviews, 2022, 06-21, Volume: 6 Topics: COVID-19; Humans; Ivermectin; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index	2022
Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials. Medicine, 2022, Oct-14, Volume: 101, Issue:41 Topics: Colchicine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Doxycycline; Humans; Imatinib Mesylate; Immunization, Passive; Immunoglobulins, Intravenous; Interferon beta-1b; Ivermectin; Lopinavir; Methylprednisolone; Network Meta-Analysis; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir	2022
Ivermectin's Role in the Prevention of COVID-19: A Systematic Review and Meta-Analysis. Journal of clinical pharmacology, 2023, Volume: 63, Issue:3 Topics: Bias; COVID-19; Humans; Ivermectin; Odds Ratio; Research Design	2023
COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics). Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2023, Volume: 19, Issue:1 Topics: Antiviral Agents; COVID-19; Humans; Ivermectin; Pandemics; SARS-CoV-2; Xenobiotics	2023
A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? Inflammopharmacology, 2023, Volume: 31, Issue:1 Topics: Antiviral Agents; COVID-19; Humans; Ivermectin; SARS-CoV-2	2023
Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy? Epilepsia, 2023, Volume: 64, Issue:3 Topics: Alcoholism; Animals; Antiparasitic Agents; COVID-19; Epilepsy; Humans; Ivermectin; Mammals	2023
Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection. GeroScience, 2023, Volume: 45, Issue:4 Topics: COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome	2023
Against Authority: The Bioethics of Ivermectin Use for COVID-19 Infection. American journal of therapeutics, 2023, May-01, Volume: 30, Issue:3 Topics: Bioethics; COVID-19; Humans; Ivermectin; Pandemics	2023
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. European journal of clinical pharmacology, 2023, Volume: 79, Issue:6 Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; Dexamethasone; Drug Repositioning; Humans; Hydroxychloroquine; Ivermectin; Methylprednisolone; Pandemics; Reproducibility of Results; SARS-CoV-2	2023
Quality of clinical evidence and political justifications of ivermectin mass distribution of COVID-19 kits in eight Latin American countries. BMJ global health, 2023, Volume: 8, Issue:5 Topics: COVID-19; Government; Hospitalization; Humans; Ivermectin; Latin America	2023
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). Annals of clinical microbiology and antimicrobials, 2023, Aug-07, Volume: 22, Issue:1 Topics: Antiviral Agents; Brazil; Communicable Diseases; COVID-19; Humans; Hydroxychloroquine; Ivermectin; Pandemics; Ritonavir; SARS-CoV-2; United States	2023
Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis. BMJ open respiratory research, 2023, Volume: 10, Issue:1 Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Humans; Hydroxychloroquine; Ivermectin; Pandemics; Primary Prevention; SARS-CoV-2	2023
The Use of Antimicrobial Drug in Patients During the COVID-19 Pandemic: A Meta-Analysis. Alternative therapies in health and medicine, 2023, Volume: 29, Issue:8 Topics: Anti-Bacterial Agents; Azithromycin; COVID-19; Humans; Ivermectin; Pandemics	2023
Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials. Scientific reports, 2023, 10-10, Volume: 13, Issue:1 Topics: COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; Randomized Controlled Trials as Topic; SARS-CoV-2	2023
Antiviral treatment of COVID-19 Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Thiazoles	2020
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells, 2020, 09-15, Volume: 9, Issue:9 Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Dengue; Dengue Virus; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vero Cells; Zika Virus; Zika Virus Infection	2020
Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2. Current topics in medicinal chemistry, 2020, Volume: 20, Issue:26 Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Gene Expression; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Immunization, Passive; Ivermectin; Models, Molecular; Niclosamide; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Protein Interaction Domains and Motifs; Protein Structure, Secondary; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Spike Glycoprotein, Coronavirus; Viral Vaccines	2020
Familiar Dermatologic Drugs as Therapies for COVID-19. Actas dermo-sifiliograficas, 2021, Volume: 112, Issue:2 Topics: Androgen Antagonists; Antimalarials; Antioxidants; Antiparasitic Agents; Chloroquine; Cinchona; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ivermectin; Melatonin; SARS-CoV-2; Virus Internalization	2021
Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2020, Volume: 23 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Drug Therapy, Combination; Humans; Ivermectin; Treatment Outcome	2020
One year update on the COVID-19 pandemic: Where are we now? Acta tropica, 2021, Volume: 214 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses	2021
Possible treatment and strategies for COVID-19: review and assessment. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:23 Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiparasitic Agents; Antiviral Agents; Cannabinoids; Chloroquine; Complement Inactivating Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Pyrazines; Ritonavir; SARS-CoV-2; Teicoplanin; Tetracyclines; Thiazoles	2020
Antiviral treatment in COVID-19: which is the most promising?-a narrative review. Annals of palliative medicine, 2021, Volume: 10, Issue:1 Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles	2021
From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? Journal of travel medicine, 2021, 02-23, Volume: 28, Issue:2 Topics: Animals; Antiparasitic Agents; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Ivermectin; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2	2021
The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacological reports : PR, 2021, Volume: 73, Issue:5 Topics: Antiparasitic Agents; COVID-19; Humans; Ivermectin; Randomized Controlled Trials as Topic; SARS-CoV-2	2021
Treatment of COVID-19: a review of current and prospective pharmacotherapies. British journal of hospital medicine (London, England : 2005), 2021, Mar-02, Volume: 82, Issue:3 Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Azetidines; Colchicine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Dexamethasone; Glucocorticoids; Humans; Immunization, Passive; Immunologic Factors; Ivermectin; Janus Kinase Inhibitors; Platelet Aggregation Inhibitors; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides	2021
Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ (Clinical research ed.), 2021, 04-26, Volume: 373 Topics: Anti-Infective Agents; Carrageenan; Chemoprevention; COVID-19; Global Health; Humans; Hydroxychloroquine; Ivermectin; SARS-CoV-2; Treatment Outcome; Uncertainty	2021
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. Epilepsy research, 2021, Volume: 174 Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inducers; Dexamethasone; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Epilepsy; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Ivermectin; Lopinavir; Pyrazines; Ritonavir; SARS-CoV-2	2021
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American journal of therapeutics, 2021, 06-21, Volume: 28, Issue:4 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome	2021
Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review. The Annals of pharmacotherapy, 2022, Volume: 56, Issue:3 Topics: Ambulatory Care; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; Disease Progression; Humans; Interferons; Ivermectin; Nitro Compounds; Polyethylene Glycols; Thiazoles	2022
Ivermectin for preventing and treating COVID-19. The Cochrane database of systematic reviews, 2021, 07-28, Volume: 7 Topics: Antiparasitic Agents; Antiviral Agents; Cause of Death; COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; Placebos; Post-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Time Factors; Treatment Outcome	2021
A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 142 Topics: Antiviral Agents; Ascorbic Acid; Cannabidiol; COVID-19; COVID-19 Drug Treatment; Dietary Supplements; Doxycycline; Drug Repositioning; Drug Therapy, Combination; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome; Vitamin D; Zinc	2021
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. American journal of therapeutics, 2021, 04-22, Volume: 28, Issue:3 Topics: Antiparasitic Agents; COVID-19; COVID-19 Drug Treatment; Disease Transmission, Infectious; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome	2021
Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection. Current research in translational medicine, 2021, Volume: 69, Issue:4 Topics: Antiviral Agents; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Drug Repositioning; Humans; Ivermectin; Meta-Analysis as Topic; Multicenter Studies as Topic; Practice Guidelines as Topic; Protein Transport; Randomized Controlled Trials as Topic; RNA Viruses; SARS-CoV-2; Time Factors; Treatment Outcome	2021

Trials

27 trial(s) available for dextrothyroxine and 2019 Novel Coronavirus Disease

Article	Year
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:12 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome; Viral Load	2021
Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial. Trials, 2021, Sep-06, Volume: 22, Issue:1 Topics: COVID-19; Female; Humans; Ivermectin; Multicenter Studies as Topic; Pregnancy; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome; Zinc	2021
Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina. American journal of therapeutics, 2021, 08-16, Volume: 28, Issue:5 Topics: Adult; Antiparasitic Agents; Antiviral Agents; Argentina; Carrageenan; COVID-19; Female; Health Personnel; Humans; Ivermectin; Male; Pre-Exposure Prophylaxis; SARS-CoV-2; Treatment Outcome	2021
Effectiveness and safety of ivermectin in the treatment of COVID-19: protocol for a systematic review and meta-analysis. BMJ open, 2021, 09-17, Volume: 11, Issue:9 Topics: COVID-19; Humans; Ivermectin; Meta-Analysis as Topic; Review Literature as Topic; SARS-CoV-2; Systematic Reviews as Topic; Treatment Outcome	2021
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. International journal of antimicrobial agents, 2022, Volume: 59, Issue:2 Topics: Adult; Antiparasitic Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Drug Repositioning; Female; Humans; Ivermectin; Male; Middle Aged; SARS-CoV-2; Treatment Outcome; Viral Load	2022
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial. JAMA internal medicine, 2022, 04-01, Volume: 182, Issue:4 Topics: Adult; COVID-19; Disease Progression; Female; Hospital Mortality; Humans; Ivermectin; Middle Aged; SARS-CoV-2; Treatment Outcome	2022
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial. Trials, 2022, Aug-26, Volume: 23, Issue:1 Topics: Adult; COVID-19; Double-Blind Method; Humans; Ivermectin; Middle Aged; Pandemics; SARS-CoV-2; Treatment Outcome	2022
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. The New England journal of medicine, 2022, 08-18, Volume: 387, Issue:7 Topics: Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Double-Blind Method; Female; Fluvoxamine; Humans; Hypoxia; Ivermectin; Male; Metformin; Middle Aged; Obesity; Overweight; Pregnancy; Pregnancy Complications, Infectious; SARS-CoV-2	2022
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA, 2022, 10-25, Volume: 328, Issue:16 Topics: Adult; Ambulatory Care; Anti-Infective Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Double-Blind Method; Drug Repositioning; Female; Hospitalization; Humans; Ivermectin; Male; Middle Aged; Recovery of Function; SARS-CoV-2; Time Factors; Treatment Outcome	2022
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial. BMC infectious diseases, 2022, Dec-08, Volume: 22, Issue:1 Topics: COVID-19; Disease Progression; Humans; Ivermectin; SARS-CoV-2; United States	2022
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV). eLife, 2023, 02-21, Volume: 12 Topics: Adult; Antiviral Agents; COVID-19; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome	2023
One versus two doses of ivermectin-based mass drug administration for the control of scabies: A cluster randomised non-inferiority trial. PLoS neglected tropical diseases, 2023, Volume: 17, Issue:3 Topics: Australia; COVID-19; Humans; Impetigo; Ivermectin; Mass Drug Administration; Pandemics; Scabies	2023
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. The Lancet. Infectious diseases, 2023, Volume: 23, Issue:10 Topics: Adult; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Female; Fluvoxamine; Humans; Incidence; Ivermectin; Male; Metformin; Middle Aged; Outpatients; Post-Acute COVID-19 Syndrome; Pregnancy; SARS-CoV-2; Treatment Outcome	2023
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol Trials, 2020, Jun-08, Volume: 21, Issue:1 Topics: Adolescent; Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Evaluation Studies as Topic; Female; Humans; Ivermectin; Male; Middle Aged; Pandemics; Pilot Projects; Pneumonia, Viral; Randomized Controlled Trials as Topic; Risk Factors; SARS-CoV-2; Time Factors; Viral Load; Young Adult	2020
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials, 2020, Nov-24, Volume: 21, Issue:1 Topics: Adult; Antiparasitic Agents; Argentina; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Female; Hospitalization; Humans; Ivermectin; Male; Pandemics; Placebos; Prospective Studies; SARS-CoV-2; Time Factors	2020
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 103 Topics: Adult; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Female; Humans; Ivermectin; Male; Middle Aged; SARS-CoV-2	2021
The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 2021, Jan-04, Volume: 22, Issue:1 Topics: Administration, Oral; Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Intensive Care Units; Interferon beta-1a; Iran; Ivermectin; Length of Stay; Lopinavir; Male; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Severity of Illness Index	2021
Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. QJM : monthly journal of the Association of Physicians, 2022, Jan-05, Volume: 114, Issue:11 Topics: COVID-19; Double-Blind Method; Humans; Ivermectin; Nigeria; Oxygen Saturation; RNA, Viral; SARS-CoV-2; Treatment Outcome	2022
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. Pathogens and global health, 2021, Volume: 115, Issue:4 Topics: Adult; Aged; Antimalarials; Antiparasitic Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Female; Humans; Hydroxychloroquine; Inpatients; Ivermectin; Male; Middle Aged	2021
Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials, 2021, Apr-09, Volume: 22, Issue:1 Topics: COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Humans; Ivermectin; Multicenter Studies as Topic; Nasopharynx; Peru; Polymerase Chain Reaction; Randomized Controlled Trials as Topic; RNA, Viral; Treatment Outcome	2021
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC infectious diseases, 2021, May-04, Volume: 21, Issue:1 Topics: Aged; Amides; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; Azithromycin; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Ivermectin; Male; Middle Aged; Pneumonia, Viral; Prospective Studies; Pyrazines; Single-Blind Method; Treatment Outcome	2021
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. The Journal of international medical research, 2021, Volume: 49, Issue:5 Topics: Adult; COVID-19; Doxycycline; Female; Humans; Ivermectin; Male; SARS-CoV-2; Treatment Outcome	2021
Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. Clinical therapeutics, 2021, Volume: 43, Issue:6 Topics: Adult; COVID-19; Humans; Iran; Ivermectin; Male; Pandemics; SARS-CoV-2; Young Adult	2021
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. Viruses, 2021, 05-26, Volume: 13, Issue:6 Topics: Adult; Antiviral Agents; Asymptomatic Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Ivermectin; Lebanon; Male; SARS-CoV-2; Treatment Outcome; Viral Load	2021
Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. Journal of medical virology, 2021, Volume: 93, Issue:10 Topics: Adult; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Egypt; Female; Humans; Ivermectin; Length of Stay; Male; Middle Aged; Respiration, Artificial; SARS-CoV-2; Treatment Outcome	2021
Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19. International journal of nanomedicine, 2021, Volume: 16 Topics: Adult; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Egypt; Female; Fever; Humans; Ivermectin; Male; Middle Aged; Nanostructures; Nasal Sprays; Nasopharynx; Prospective Studies; Respiratory Tract Diseases; Treatment Outcome	2021
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC infectious diseases, 2021, Jul-02, Volume: 21, Issue:1 Topics: Adult; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Double-Blind Method; Female; Hospitalization; Humans; Ivermectin; Length of Stay; Male; Middle Aged; Nasopharynx; Placebos; Treatment Outcome	2021

Other Studies

146 other study(ies) available for dextrothyroxine and 2019 Novel Coronavirus Disease

Article	Year
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460, July 2021. American journal of therapeutics, 2021, 08-27, Volume: 28, Issue:5 Topics: Antiviral Agents; COVID-19; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome; United States	2021
Strongyloidiasis in immunocompromised migrants to non-endemic countries in the era of COVID-19: what is the role for presumptive ivermectin? Journal of travel medicine, 2022, 01-17, Volume: 29, Issue:1 Topics: COVID-19; Humans; Immunocompromised Host; Ivermectin; SARS-CoV-2; Strongyloidiasis; Transients and Migrants	2022
Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells. Antimicrobial agents and chemotherapy, 2022, 01-18, Volume: 66, Issue:1 Topics: Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; Epithelial Cells; Humans; Ivermectin; Macrolides; SARS-CoV-2; Vero Cells; Virus Replication	2022
'I hope you die': how the COVID pandemic unleashed attacks on scientists. Nature, 2021, Volume: 598, Issue:7880 Topics: Azithromycin; Bullying; Communication; COVID-19; Female; Health Policy; Humans; Hydroxychloroquine; Ivermectin; Male; Pandemics; Politics; Research Personnel; Violence	2021
Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19. The New England journal of medicine, 2021, 12-02, Volume: 385, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antiparasitic Agents; Confusion; COVID-19; COVID-19 Drug Treatment; Female; Gastrointestinal Diseases; Hospitalization; Humans; Ivermectin; Male; Middle Aged; Oregon; Poison Control Centers; Seizures	2021
African scientists race to test COVID drugs - but face major hurdles. Nature, 2021, Volume: 599, Issue:7883 Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization	2021
Ivermectin for COVID-19: Concerns during pregnancy. Reproductive toxicology (Elmsford, N.Y.), 2022, Volume: 107 Topics: COVID-19; Female; Humans; Ivermectin; Pregnancy; SARS-CoV-2	2022
Effectiveness and safety of Ivermectin in COVID-19 patients: A prospective study at a safety-net hospital. Journal of medical virology, 2022, Volume: 94, Issue:4 Topics: Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Female; Hospital Mortality; Humans; Intensive Care Units; Ivermectin; Length of Stay; Logistic Models; Male; Middle Aged; Propensity Score; Prospective Studies; Respiration, Artificial; Safety-net Providers; Young Adult	2022
Is there any prophylactic role for ivermectin in COVID-19-A literature summary. Journal of cosmetic dermatology, 2022, Volume: 21, Issue:1 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2; Time Factors	2022
Concomitant SARS-CoV-2 infection and crusted scabies in a 4-month infant. Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:3 Topics: COVID-19; Humans; Immunocompromised Host; Infant; Ivermectin; SARS-CoV-2; Scabies	2022
Effects of the COVID-19 pandemic on head lice and scabies infestation dynamics: a population-based study in France. Clinical and experimental dermatology, 2022, Volume: 47, Issue:5 Topics: Animals; Communicable Disease Control; COVID-19; Humans; Ivermectin; Lice Infestations; Pandemics; Pediculus; SARS-CoV-2; Scabies	2022
Ivermectin: a pathway out of the pandemic or another dead end? Expert review of anti-infective therapy, 2022, Volume: 20, Issue:5 Topics: COVID-19; Humans; Ivermectin; Pandemics; SARS-CoV-2	2022
Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19. American journal of therapeutics, 2021, 12-07, Volume: 29, Issue:1 Topics: Antiparasitic Agents; COVID-19; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome	2021
American College of Medical Toxicology (ACMT) Cautions Against Off-Label Prescribing of Ivermectin for the Prevention or Treatment of COVID-19. Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2022, Volume: 18, Issue:1 Topics: COVID-19; Humans; Ivermectin; Off-Label Use; SARS-CoV-2; United States	2022
Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022, Volume: 28, Issue:4 Topics: COVID-19; COVID-19 Drug Treatment; Gastrointestinal Diseases; Humans; Ivermectin; Propensity Score; Respiration, Artificial; SARS-CoV-2	2022
Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever. Nature medicine, 2022, Volume: 28, Issue:1 Topics: Antimalarials; Antiparasitic Agents; Communicable Disease Control; Contact Tracing; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Glucocorticoids; Humans; Hydroxychloroquine; Information Dissemination; Ivermectin; Meta-Analysis as Topic; Peer Review, Research; Preprints as Topic; Retraction of Publication as Topic; SARS-CoV-2; Scientific Misconduct	2022
From hydroxychloroquine to ivermectin: how unproven "cures" can go viral. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:4 Topics: COVID-19; Humans; Hydroxychloroquine; Ivermectin; SARS-CoV-2	2022
Genome-wide analyses reveal the detrimental impacts of SARS-CoV-2 viral gene Orf9c on human pluripotent stem cell-derived cardiomyocytes. Stem cell reports, 2022, 03-08, Volume: 17, Issue:3 Topics: Action Potentials; Adenosine Triphosphate; Apoptosis; Coronavirus Nucleocapsid Proteins; COVID-19; Down-Regulation; Genome-Wide Association Study; Humans; Ivermectin; Meclizine; Myocytes, Cardiac; Phosphoproteins; Pluripotent Stem Cells; Protein Interaction Maps; RNA, Messenger; SARS-CoV-2; Signal Transduction; Transcriptome; Up-Regulation	2022
Unexpected consequences of SARS-CoV-2 pandemic: scabies infestation. Clinical and experimental dermatology, 2022, Volume: 47, Issue:6 Topics: COVID-19; Humans; Ivermectin; Pandemics; SARS-CoV-2; Scabies	2022
Viral Load Reduction and High-Dose Ivermectin in Early Treatment: A Reappraisal. International journal of antimicrobial agents, 2022, Volume: 59, Issue:5 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2; Viral Load	2022
Reply to: Viral load reduction and high-dose ivermectin in early treatment: a reappraisal. International journal of antimicrobial agents, 2022, Volume: 59, Issue:5 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2; Viral Load	2022
Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19. American journal of therapeutics, 2022, 02-10, Volume: 29, Issue:2 Topics: COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; Meta-Analysis as Topic; Treatment Outcome	2022
Unethical studies of ivermectin for covid-19. BMJ (Clinical research ed.), 2022, 04-14, Volume: 377 Topics: Antiparasitic Agents; Antiviral Agents; COVID-19; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome	2022
Scabies increase during the COVID-19 pandemic: should we change our treatment strategy during the pandemic? Annals of parasitology, 2022, Volume: 68, Issue:1 Topics: Communicable Disease Control; COVID-19; Humans; Insecticides; Ivermectin; Pandemics; Permethrin; Scabies	2022
Nanovectorization of Ivermectin to avoid overdose of drugs. Journal of biomolecular structure & dynamics, 2023, Volume: 41, Issue:10 Topics: COVID-19; Drug-Related Side Effects and Adverse Reactions; Humans; Ivermectin; Oxides; SARS-CoV-2	2023
Severe cutaneous adverse reactions associated with systemic ivermectin: A pharmacovigilance analysis. The Journal of dermatology, 2022, Volume: 49, Issue:8 Topics: Cicatrix; COVID-19; Female; Humans; Ivermectin; Male; Middle Aged; Pharmacovigilance; Stevens-Johnson Syndrome	2022
Ivermectin associated adverse events in the treatment and prevention of COVID-19 reported to the FACT pharmacovigilance project. Clinical toxicology (Philadelphia, Pa.), 2022, Volume: 60, Issue:8 Topics: Centers for Disease Control and Prevention, U.S.; COVID-19; COVID-19 Drug Treatment; Hospitalization; Humans; Ivermectin; Pharmacovigilance; United States	2022
Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT. Computational biology and chemistry, 2022, Volume: 99 Topics: Antiviral Agents; COVID-19; Drug Combinations; Humans; Ivermectin; Lactams; Leucine; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Pandemics; Peptide Hydrolases; Proline; Protease Inhibitors; Ritonavir; SARS-CoV-2; Thermodynamics	2022
Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening. Molecular diversity, 2023, Volume: 27, Issue:3 Topics: COVID-19; Drug Repositioning; Humans; Ivermectin; Molecular Docking Simulation; Molecular Dynamics Simulation; Pharmacophore; SARS-CoV-2	2023
Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. PloS one, 2022, Volume: 17, Issue:6 Topics: Azithromycin; Calcitriol; Colchicine; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Humans; Hydroxychloroquine; Ivermectin; Pandemics	2022
The Effect of Ivermectin on Cases of COVID-19. Cardiovascular revascularization medicine : including molecular interventions, 2022, Volume: 44 Topics: Adult; Antiviral Agents; COVID-19; Humans; Ivermectin	2022
Factors Associated With Drug Consumption Without Scientific Evidence in Patients With Mild COVID-19 in Peru. Journal of patient safety, 2022, 12-01, Volume: 18, Issue:8 Topics: Adult; COVID-19; Cross-Sectional Studies; Humans; Ivermectin; Peru; Prevalence	2022
Decreases in scabies and lice cases among the pediatric and adult populations during COVID-19. Pediatric dermatology, 2022, Volume: 39, Issue:5 Topics: Adult; Animals; Child; Communicable Disease Control; COVID-19; Cross-Sectional Studies; Humans; Insecticides; Ivermectin; Lice Infestations; Pandemics; Permethrin; Phthiraptera; Scabies	2022
Central Effects of Ivermectin in Alleviation of Covid-19-induced Dysauto-nomia. Current drug targets, 2022, Volume: 23, Issue:13 Topics: Animals; Bees; COVID-19; gamma-Aminobutyric Acid; Humans; Hypoxia; Ivermectin; Primary Dysautonomias; SARS-CoV-2	2022
Despite the use of ivermectin during the COVID pandemic, scabies keeps playing tricks with us. Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:1 Topics: Administration, Oral; COVID-19; Humans; Insecticides; Ivermectin; Pandemics; Scabies	2023
Understanding the widespread use of veterinary ivermectin for Chagas disease, underlying factors and implications for the COVID-19 pandemic: a convergent mixed-methods study. BMJ open, 2022, 09-17, Volume: 12, Issue:9 Topics: Adult; Chagas Disease; COVID-19; Cross-Sectional Studies; Humans; Ivermectin; Middle Aged; Pandemics	2022
Letter in reply: more power to ivermectin multidrug therapy. Future microbiology, 2022, Volume: 17 Topics: Antiviral Agents; COVID-19; Drug Therapy, Combination; Humans; Ivermectin; Leprostatic Agents; SARS-CoV-2	2022
COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil. Journal of applied oral science : revista FOB, 2022, Volume: 30 Topics: Brazil; Chloroquine; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Dentists; Humans; Incidence; Ivermectin; Pandemics; SARS-CoV-2; Surveys and Questionnaires; Vaccination; Vaccines; Vitamin D; Zinc	2022
The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling. Drug metabolism and personalized therapy, 2023, 03-01, Volume: 38, Issue:1 Topics: Adult; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Ivermectin; Lopinavir; Ritonavir	2023
Ivermectin exposures reported to the Poisons Information Helpline in South Africa during the COVID-19 pandemic. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2022, 08-02, Volume: 112, Issue:8 Topics: Antiparasitic Agents; COVID-19; Humans; Ivermectin; Pandemics; Poisons; SARS-CoV-2; South Africa	2022
Incidence of and Ivermectin Prescription Trends for COVID-19 in Japan. Journal of general internal medicine, 2023, Volume: 38, Issue:4 Topics: COVID-19; Humans; Incidence; Ivermectin; Japan	2023
Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19. Clinical toxicology (Philadelphia, Pa.), 2022, Volume: 60, Issue:12 Topics: COVID-19; Female; Humans; Ivermectin; Male; Middle Aged; Neurotoxicity Syndromes; Pandemics; Retrospective Studies; Tablets	2022
Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021. The Journal of antimicrobial chemotherapy, 2022, 12-23, Volume: 78, Issue:1 Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Interrupted Time Series Analysis; Ivermectin; Outpatients; Pandemics; Retrospective Studies	2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24 Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin	2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply. The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24 Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin	2022
Ivermectin Treatment for Covid-19. The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24 Topics: COVID-19; Humans; Ivermectin; Patients	2022
Ivermectin Treatment for Covid-19. The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24 Topics: COVID-19; Humans; Ivermectin; Patients	2022
Ivermectin Treatment for Covid-19. Reply. The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24 Topics: COVID-19; Humans; Ivermectin; Patients	2022
Ivermectin Treatment for Covid-19. The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24 Topics: COVID-19; Humans; Ivermectin; Patients	2022
A Case of Pharmaceutical Messianism Amidst the COVID-19 Pandemic: An Infodemiological Study of Ivermectin in the Philippines. Policy, politics & nursing practice, 2023, Volume: 24, Issue:1 Topics: COVID-19; Humans; Ivermectin; Pandemics; Pharmaceutical Preparations; Philippines; SARS-CoV-2	2023
Impact of misinformation on ivermectin internet searches and prescribing trends during COVID-19. Journal of public health (Oxford, England), 2023, 08-28, Volume: 45, Issue:3 Topics: Communication; COVID-19; Humans; Internet; Ivermectin; SARS-CoV-2	2023
Ivermectin: Not yet an approved COVID-19 treatment. Nursing, 2023, Jan-01, Volume: 53, Issue:1 Topics: COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome	2023
The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic. The Journal of antimicrobial chemotherapy, 2023, 02-01, Volume: 78, Issue:2 Topics: COVID-19; Epidemics; Humans; Hydroxychloroquine; Ivermectin	2023
A protocol of trial of ivermectin in COVID-19 treatment critically changed after its completion. Journal of medical virology, 2023, Volume: 95, Issue:2 Topics: Clinical Trial Protocols as Topic; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome	2023
Death from COVID-19 of a 57-year-old man refusing medical care and self-medicating with ivermectin. Central European journal of public health, 2022, Volume: 30, Issue:4 Topics: Aged; COVID-19; Humans; Ivermectin; Male; Middle Aged; SARS-CoV-2	2022
Dispensing of Ivermectin From Veterans Administration Pharmacies During the COVID-19 Pandemic. JAMA network open, 2023, 02-01, Volume: 6, Issue:2 Topics: COVID-19; Humans; Ivermectin; Pandemics; Pharmacies; United States; United States Department of Veterans Affairs	2023
The political polarization of COVID-19 treatments among physicians and laypeople in the United States. Proceedings of the National Academy of Sciences of the United States of America, 2023, 02-14, Volume: 120, Issue:7 Topics: COVID-19; COVID-19 Drug Treatment; Critical Care; Humans; Ivermectin; Politics; United States	2023
At a Higher Dose and Longer Duration, Ivermectin Still Not Effective Against COVID-19. JAMA, 2023, 03-21, Volume: 329, Issue:11 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2; Uncertainty	2023
The Ethics of Clinical Research: Managing Persistent Uncertainty. JAMA, 2023, 03-21, Volume: 329, Issue:11 Topics: COVID-19; Decision Making; Ethics, Medical; Humans; Ivermectin; Uncertainty	2023
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA, 2023, 03-21, Volume: 329, Issue:11 Topics: COVID-19; COVID-19 Vaccines; Female; Humans; Ivermectin; Male; Middle Aged; Outpatients; SARS-CoV-2; Vaccines	2023
The Use of Ivermectin in the Treatment of COVID-19. Journal of general internal medicine, 2023, Volume: 38, Issue:6 Topics: Antiviral Agents; COVID-19; Humans; Ivermectin; Treatment Outcome	2023
Electrochemical Characterisation and Confirmation of Antioxidative Properties of Ivermectin in Biological Medium. Molecules (Basel, Switzerland), 2023, Feb-24, Volume: 28, Issue:5 Topics: Anthelmintics; Antioxidants; Carbon; COVID-19; Electrodes; Humans; Ivermectin; Oxidation-Reduction; SARS-CoV-2; Zika Virus; Zika Virus Infection	2023
Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration. PLoS neglected tropical diseases, 2023, Volume: 17, Issue:4 Topics: Adult; Animals; COVID-19; Cross-Sectional Studies; Female; Humans; Ivermectin; Male; Mass Drug Administration; Microfilariae; Onchocerciasis; Pandemics; Prevalence	2023
Prevalence of Ivermectin use to prevent COVID-19 during the pandemic in Mato Grosso: cross-sectional home-based study. Revista brasileira de epidemiologia = Brazilian journal of epidemiology, 2023, Volume: 26 Topics: Brazil; COVID-19; Cross-Sectional Studies; Humans; Ivermectin; Pandemics; Prevalence; SARS-CoV-2; Seroepidemiologic Studies	2023
Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model. The Journal of antibiotics, 2023, Volume: 76, Issue:8 Topics: Animals; COVID-19; Cricetinae; Ivermectin; Lung; Mesocricetus; SARS-CoV-2	2023
COVID-19 update: Metformin to prevent long COVID? The Medical letter on drugs and therapeutics, 2023, 05-29, Volume: 65, Issue:1677 Topics: COVID-19; Humans; Hypoglycemic Agents; Ivermectin; Metformin; Post-Acute COVID-19 Syndrome; SARS-CoV-2	2023
Ivermectin Effect on In-Hospital Mortality and Need for Respiratory Support in COVID-19 Pneumonia: Propensity Score-Matched Retrospective Study. Viruses, 2023, 05-10, Volume: 15, Issue:5 Topics: Animals; COVID-19; Hospital Mortality; Humans; Ivermectin; Propensity Score; Retrospective Studies; Strongyloides stercoralis	2023
Ivermectin drug induced liver injury. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2023, 06-05, Volume: 113, Issue:6 Topics: Chemical and Drug Induced Liver Injury; COVID-19; Female; Humans; Ivermectin; Liver; South Africa	2023
Therapeutic Messianism: Belladonna for Heroin Withdrawal, Ivermectin for COVID-19 Infection. American journal of therapeutics, 2023, 05-01, Volume: 30, Issue:3 Topics: Atropa belladonna; COVID-19; Heroin; Heroin Dependence; Humans; Ivermectin; Substance Withdrawal Syndrome	2023
Patch-clamp studies and cell viability assays suggest a distinct site for viroporin inhibitors on the E protein of SARS-CoV-2. Virology journal, 2023, Jul-08, Volume: 20, Issue:1 Topics: Cell Survival; COVID-19; HEK293 Cells; Humans; Ivermectin; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Viroporin Proteins	2023
Computational Prediction of the Interaction of Ivermectin with Fibrinogen. International journal of molecular sciences, 2023, Jul-14, Volume: 24, Issue:14 Topics: COVID-19; Fibrin; Fibrinogen; Hemostatics; Humans; Ivermectin; Molecular Docking Simulation; Post-Acute COVID-19 Syndrome; SARS-CoV-2; Thrombosis	2023
Wastewater surveillance of pharmaceuticals during the COVID-19 pandemic in Mexico City and the Mezquital Valley: A comprehensive environmental risk assessment. The Science of the total environment, 2023, Nov-20, Volume: 900 Topics: Azithromycin; COVID-19; Dexamethasone; Environmental Monitoring; Famotidine; Humans; Ivermectin; Mexico; Pandemics; Pharmaceutical Preparations; Risk Assessment; Sewage; Wastewater; Wastewater-Based Epidemiological Monitoring; Water Pollutants, Chemical	2023
Fatal Disseminated Strongyloidiasis in an Immunosuppressed Patient During COVID-19 Pandemic. Acta parasitologica, 2023, Volume: 68, Issue:3 Topics: Aged; Animals; COVID-19; Female; Humans; Ivermectin; Pandemics; Strongyloides stercoralis; Strongyloidiasis	2023
Ivermectin adsorption by commercial charcoal in batch and fixed-bed operations. Environmental science and pollution research international, 2023, Volume: 30, Issue:42 Topics: Adsorption; Charcoal; COVID-19; Humans; Hydrogen-Ion Concentration; Ivermectin; Kinetics; Pandemics; Thermodynamics; Water Pollutants, Chemical	2023
Effects of the suspension of mass drug administration during the COVID-19 pandemic on onchocerciasis prevalence in the Bandjoun and Massangam health districts, West Region of Cameroon. Acta tropica, 2023, Volume: 246 Topics: Aged; Animals; Cameroon; COVID-19; Female; Humans; Ivermectin; Male; Mass Drug Administration; Microfilariae; Onchocerciasis; Pandemics; Prevalence	2023
A cross-lingual analysis on the spread of misinformation using the case of Ivermectin as a treatment for Covid-19. Scientific reports, 2023, 09-06, Volume: 13, Issue:1 Topics: COVID-19; Humans; Ivermectin; Language; Pandemics	2023
Implementation and Outcomes of an Empiric Ivermectin Strongyloides Treatment Protocol for Patients Receiving High-Dose Corticosteroids for Severe COVID-19. The American journal of tropical medicine and hygiene, 2023, 09-06, Volume: 109, Issue:3 Topics: Adrenal Cortex Hormones; Animals; Asymptomatic Infections; Clinical Protocols; COVID-19; Humans; Inpatients; Ivermectin; Strongyloides stercoralis; Strongyloidiasis	2023
Off-label drug use during the COVID-19 pandemic in Africa: topic modelling and sentiment analysis of ivermectin in South Africa and Nigeria as a case study. Journal of the Royal Society, Interface, 2023, Volume: 20, Issue:206 Topics: COVID-19; Humans; Ivermectin; Nigeria; Off-Label Use; Pandemics; Sentiment Analysis; South Africa	2023
Misinformation, Trust, and Use of Ivermectin and Hydroxychloroquine for COVID-19. JAMA health forum, 2023, 09-01, Volume: 4, Issue:9 Topics: Adult; Communication; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Female; Humans; Hydroxychloroquine; Ivermectin; Male; Pandemics; Trust; United States	2023
Perceptions and acceptability of co-administered albendazole, ivermectin and azithromycin mass drug administration, among the health workforce and recipient communities in Ethiopia. PLoS neglected tropical diseases, 2023, Volume: 17, Issue:10 Topics: Adolescent; Albendazole; Azithromycin; COVID-19; COVID-19 Drug Treatment; Ethiopia; Health Workforce; Humans; Ivermectin; Mass Drug Administration	2023
Ivermectin for preventing and treating COVID-19. Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, 2023, Volume: 35, Issue:5 Topics: COVID-19; Humans; Ivermectin	2023
Pharmacogenomic Landscape of Ivermectin and Selective Antioxidants: Exploring Gene Interplay in the Context of Long COVID. International journal of molecular sciences, 2023, Oct-23, Volume: 24, Issue:20 Topics: Anthocyanins; Antioxidants; COVID-19; Humans; Ivermectin; MicroRNAs; Pandemics; Pharmacogenetics; Post-Acute COVID-19 Syndrome	2023
In Vitro Analysis of SARS-CoV-2 Spike Protein and Ivermectin Interaction. International journal of molecular sciences, 2023, Nov-16, Volume: 24, Issue:22 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2; Spike Glycoprotein, Coronavirus; United States	2023
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research, 2020, Volume: 178 Topics: Animals; Antiviral Agents; Australia; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Approval; Humans; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vero Cells; Virus Replication	2020
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:6 Topics: Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. The American journal of tropical medicine and hygiene, 2020, Volume: 102, Issue:6 Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus	2020
Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral research, 2020, Volume: 178 Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus	2020
COVID-19 and Fake News in the Dominican Republic. The American journal of tropical medicine and hygiene, 2020, Volume: 102, Issue:6 Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Civil Disorders; Coronavirus Infections; COVID-19; Dissent and Disputes; Dominican Republic; Drug Repositioning; Humans; Hydroxychloroquine; Ivermectin; Pandemics; Pneumonia, Viral; Politics; Public Health; SARS-CoV-2; Social Media; Trust	2020
In Vitro Data of Current Therapies for SARS-CoV-2. Current medicinal chemistry, 2020, Volume: 27, Issue:27 Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Emetine; Homoharringtonine; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; SARS-CoV-2; Teicoplanin; Thiazoles	2020
Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine. Dermatologic therapy, 2020, Volume: 33, Issue:4 Topics: Acute Generalized Exanthematous Pustulosis; Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2. The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:1 Topics: Africa; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Ivermectin; Onchocerciasis, Ocular; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:7 Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of clinical microbiology and antimicrobials, 2020, 05-30, Volume: 19, Issue:1 Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus	2020
Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. Medical hypotheses, 2020, Volume: 143 Topics: Acetazolamide; Anti-Inflammatory Agents; Anticoagulants; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Diet Therapy; Humans; Immune System; Inflammation; Ivermectin; Mass Screening; NF-E2-Related Factor 2; NF-kappa B; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Resource Allocation; Risk; Sildenafil Citrate; Treatment Outcome	2020
The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin. Drug research, 2020, Volume: 70, Issue:8 Topics: Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Models, Animal; Humans; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leukemia & lymphoma, 2020, Volume: 61, Issue:10 Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Drug Repositioning; Humans; Ivermectin; Leukemia, Myeloid, Acute; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. Marine pollution bulletin, 2020, Volume: 157 Topics: Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; France; Humans; Italy; Ivermectin; Mediterranean Sea; Nematoda; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spain	2020
Management of crash and burn patients with SARS-CoV-2 associated ARDS. Journal of cardiac surgery, 2020, Volume: 35, Issue:9 Topics: Adult Stem Cells; Angiotensin-Converting Enzyme 2; Azithromycin; Blood Component Transfusion; COVID-19; Extracorporeal Membrane Oxygenation; Humans; Hydroxychloroquine; Ivermectin; Plasma; Recombinant Proteins; Respiratory Distress Syndrome; SARS-CoV-2	2020
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms? International journal of antimicrobial agents, 2020, Volume: 56, Issue:3 Topics: Anticholesteremic Agents; Antineoplastic Agents; Antiparasitic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Administration Schedule; Drug Repositioning; Host-Pathogen Interactions; Humans; Hypoglycemic Agents; Ivermectin; Lovastatin; Metformin; Nitro Compounds; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index; Thiazoles	2020
COVID-19 in pediatric cancer patients in a resource-limited setting: National data from Peru. Pediatric blood & cancer, 2021, Volume: 68, Issue:2 Topics: Adolescent; Adrenal Cortex Hormones; Antiviral Agents; Azithromycin; Child; Child, Preschool; COVID-19; COVID-19 Drug Treatment; Female; Humans; Infant; Ivermectin; Male; Neoplasms; Palliative Care; Peru; SARS-CoV-2; Treatment Outcome	2021
White paper on Ivermectin as a potential therapy for COVID-19. The Indian journal of tuberculosis, 2020, Volume: 67, Issue:3 Topics: Antiparasitic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Ivermectin; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2; Treatment Outcome	2020
Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of pharmaceutical sciences, 2020, Volume: 109, Issue:12 Topics: Administration, Oral; Animals; Antiviral Agents; Betacoronavirus; Cattle; Computer Simulation; Coronavirus Infections; COVID-19; Drug Repositioning; Humans; Ivermectin; Lung; Models, Biological; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open heart, 2020, Volume: 7, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drugs, Essential; Host-Pathogen Interactions; Humans; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome	2020
Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. Infection, 2021, Volume: 49, Issue:3 Topics: Animals; Antibodies, Monoclonal, Humanized; Antiparasitic Agents; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Feces; Female; Humans; Immunosuppressive Agents; Ivermectin; Latent Infection; Middle Aged; SARS-CoV-2; Strongyloides stercoralis; Strongyloidiasis; Treatment Outcome	2021
Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach. International journal of biological macromolecules, 2020, Nov-15, Volume: 163 Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Fidaxomicin; Humans; Ivermectin; Molecular Docking Simulation; Pandemics; Pneumonia, Viral; Rifabutin; Rifampin; RNA-Dependent RNA Polymerase; SARS-CoV-2; Virus Replication	2020
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues. Biomolecules, 2020, 09-21, Volume: 10, Issue:9 Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Antigen-Antibody Reactions; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Eflornithine; Humans; Hydrophobic and Hydrophilic Interactions; Ivermectin; L-Lactate Dehydrogenase; Models, Molecular; Molecular Docking Simulation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Proline; Protein Binding; Protein Conformation; Protein Interaction Mapping; Receptors, Glycine; Saposins; SARS-CoV-2; Sofosbuvir; Spike Glycoprotein, Coronavirus; Structure-Activity Relationship	2020
Considerations on the Article "Antiviral and Anti-Inflammatory Properties of Ivermectin and its Potential Use in COVID-19". Archivos de bronconeumologia, 2020, Volume: 56, Issue:12 Topics: Anti-Inflammatory Agents; Antiviral Agents; COVID-19; Humans; Ivermectin; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. Scientific reports, 2020, 10-13, Volume: 10, Issue:1 Topics: Administration, Inhalation; Animals; Antiparasitic Agents; Behavior, Animal; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Female; Half-Life; Ivermectin; Lung; Male; Necrosis; Pandemics; Pneumonia, Viral; Proof of Concept Study; Rats; Rats, Sprague-Dawley; Respiration Disorders	2020
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest, 2021, Volume: 159, Issue:1 Topics: Adult; Aged; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Female; Hospital Mortality; Hospitalization; Humans; Ivermectin; Male; Middle Aged; Retrospective Studies	2021
Latin America's embrace of an unproven COVID treatment is hindering drug trials. Nature, 2020, Volume: 586, Issue:7830 Topics: Animals; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Evidence-Based Medicine; Humans; Ivermectin; Latin America; Pandemics; Pneumonia, Viral; Reproducibility of Results; Retraction of Publication as Topic	2020
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PloS one, 2020, Volume: 15, Issue:11 Topics: Adult; Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Immunosuppressive Agents; Ivermectin; Male; Middle Aged; Nasopharynx; Pandemics; Pneumonia, Viral; Retrospective Studies; SARS-CoV-2; Treatment Outcome	2020
COVID-19: Panama stockpiles unproven drugs. Nature, 2020, Volume: 587, Issue:7835 Topics: COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Ivermectin; Panama; Self Care; Social Isolation; Strategic Stockpile; Uncertainty	2020
Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19? Medical hypotheses, 2021, Volume: 146 Topics: Administration, Inhalation; Anthelmintics; Anti-Inflammatory Agents; Antiviral Agents; Computer Simulation; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Ivermectin; Lung; Models, Biological; Pandemics; SARS-CoV-2	2021
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. International journal of antimicrobial agents, 2021, Volume: 57, Issue:1 Topics: Africa; Antiparasitic Agents; COVID-19; Humans; Incidence; Ivermectin	2021
Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin. Internal medicine (Tokyo, Japan), 2021, Feb-01, Volume: 60, Issue:3 Topics: COVID-19; Cytokine Release Syndrome; Cytokines; Humans; Immunoglobulins, Intravenous; Ivermectin; Lung; Male; Middle Aged; Radiography, Thoracic; Respiratory Insufficiency; SARS-CoV-2; Viral Load	2021
COVID-19 in Still's disease. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:24 Topics: Anti-Bacterial Agents; Antiparasitic Agents; Azithromycin; Blood Sedimentation; C-Reactive Protein; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Female; Ferritins; Humans; Ivermectin; Lung; Middle Aged; Quarantine; SARS-CoV-2; Still's Disease, Adult-Onset; Tomography, X-Ray Computed	2020
Deep vein thrombosis with pulmonary thromboembolism in a case of severe COVID-19 pneumonia. BMJ case reports, 2021, Jan-15, Volume: 14, Issue:1 Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Anticoagulants; Antiparasitic Agents; Antiviral Agents; Computed Tomography Angiography; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Doxycycline; Femoral Vein; Fibrin Fibrinogen Degradation Products; Glucocorticoids; Heparin, Low-Molecular-Weight; Humans; Ivermectin; Male; Methylprednisolone; Middle Aged; Oxygen Inhalation Therapy; Popliteal Vein; Pulmonary Embolism; SARS-CoV-2; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color; Venous Thrombosis	2021
Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortality. The British journal of dermatology, 2021, Volume: 184, Issue:6 Topics: Administration, Oral; Antiparasitic Agents; COVID-19; Disease Outbreaks; Humans; Ivermectin; Long-Term Care; SARS-CoV-2; Scabies	2021
Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of pharmaceutical sciences, 2021, Volume: 110, Issue:6 Topics: Administration, Oral; Animals; COVID-19; Humans; Ivermectin; Nasal Sprays; SARS-CoV-2; Swine	2021
Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases. Journal of nanoscience and nanotechnology, 2021, 04-01, Volume: 21, Issue:4 Topics: Azithromycin; Coronavirus 3C Proteases; COVID-19; Heparin; Humans; Ivermectin; Lopinavir; Molecular Docking Simulation; Oseltamivir; Ritonavir; SARS-CoV-2	2021
What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 03-06, Volume: 115, Issue:3 Topics: Communicable Disease Control; COVID-19; Disease Eradication; Filaricides; Humans; Ivermectin; Mass Drug Administration; Models, Theoretical; Neglected Diseases; Onchocerciasis; Pandemics; Prevalence; SARS-CoV-2	2021
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PloS one, 2021, Volume: 16, Issue:2 Topics: Adult; Ascorbic Acid; Case-Control Studies; Chemoprevention; COVID-19; Drug Combinations; Female; Health Personnel; Humans; India; Ivermectin; Male; Middle Aged	2021
Update to living WHO guideline on drugs for covid-19. BMJ (Clinical research ed.), 2021, 03-31, Volume: 372 Topics: Antiparasitic Agents; COVID-19; COVID-19 Drug Treatment; Guidelines as Topic; Humans; Ivermectin; Pharmaceutical Preparations; SARS-CoV-2; World Health Organization	2021
COVID-19: The Ivermectin African Enigma. Colombia medica (Cali, Colombia), 2020, Dec-30, Volume: 51, Issue:4 Topics: Africa; Antiparasitic Agents; COVID-19; Humans; Ivermectin; Onchocerciasis	2020
Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets. Journal of biomolecular structure & dynamics, 2022, Volume: 40, Issue:18 Topics: alpha Karyopherins; Antiviral Agents; COVID-19; Humans; Ivermectin; Molecular Docking Simulation; Molecular Dynamics Simulation; Peptide Hydrolases; Protease Inhibitors; SARS-CoV-2; Viral Proteins	2022
Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors. Open heart, 2021, Volume: 8, Issue:1 Topics: Anti-Inflammatory Agents; COVID-19; Humans; Ivermectin; Receptors, Glycine; SARS-CoV-2	2021
Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ evidence-based medicine, 2022, Volume: 27, Issue:3 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2	2022
COVID-19 Pandemic and Dysbiosis: Can the Ivermectin Hysteria Lead to an Increase of Autoimmune Neuroinflammatory Diseases? Critical reviews in immunology, 2020, Volume: 40, Issue:6 Topics: Autoimmune Diseases of the Nervous System; COVID-19; COVID-19 Drug Treatment; Disease Susceptibility; Dysbiosis; Humans; Ivermectin; SARS-CoV-2	2020
Ivermectin for COVID-19: Promising but not yet conclusive. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2021, 01-12, Volume: 111, Issue:3 Topics: COVID-19; Humans; Ivermectin; Pharmaceutical Preparations; SARS-CoV-2; South Africa	2021
A qualitative analysis of seven ivermectin formulations in South Africa. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2021, 02-18, Volume: 111, Issue:4 Topics: Capsules; Chromatography, High Pressure Liquid; COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; Mass Spectrometry; Qualitative Research; SARS-CoV-2; South Africa; Tablets	2021
Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study). Chest, 2021, Volume: 159, Issue:5 Topics: COVID-19; Humans; Ivermectin; Retrospective Studies; SARS-CoV-2	2021
Standard Dose Ivermectin for COVID-19. Chest, 2021, Volume: 159, Issue:5 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2	2021
Response. Chest, 2021, Volume: 159, Issue:5 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2	2021
Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Archivos de bronconeumologia, 2020, Volume: 56, Issue:12 Topics: Antiviral Agents; COVID-19; Humans; Ivermectin; Prognosis; SARS-CoV-2	2020
Revue medicale suisse, 2021, 05-19, Volume: 17, Issue:739 Topics: COVID-19; Humans; Ivermectin; SARS-CoV-2	2021
Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin. EMBO molecular medicine, 2021, 08-09, Volume: 13, Issue:8 Topics: Animals; COVID-19; Humans; Ivermectin; Lung; Pandemics; SARS-CoV-2	2021
Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible? International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 109 Topics: Antiviral Agents; COVID-19; Humans; Ivermectin; SARS-CoV-2	2021
Effect of Infodemic Regarding the Illegal Sale of Medications on the Internet: Evaluation of Demand and Online Availability of Ivermectin during the COVID-19 Pandemic. International journal of environmental research and public health, 2021, 07-13, Volume: 18, Issue:14 Topics: COVID-19; Humans; Internet; Ivermectin; Pandemics; SARS-CoV-2	2021
A five-day course of ivermectin may reduce the duration of COVID-19 illness. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 110 Topics: Antiviral Agents; COVID-19; Humans; Ivermectin; SARS-CoV-2	2021
Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature, 2021, Volume: 596, Issue:7871 Topics: Antiparasitic Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; Pandemics; Plagiarism; Preprints as Topic; Research Personnel; Retraction of Publication as Topic; Sample Size; Scientific Misconduct; World Health Organization	2021
Reply to Banno et al and Padhi et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 03-23, Volume: 74, Issue:6 Topics: COVID-19; Humans; Ivermectin; Randomized Controlled Trials as Topic	2022
Ivermectin for Coronavirus Disease 2019: Yet to Be Well Evaluated Before Clinical Use. Clinical therapeutics, 2021, Volume: 43, Issue:9 Topics: Antiviral Agents; COVID-19; Humans; Ivermectin; SARS-CoV-2	2021
Response to Letter Regarding Article, "Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial". Clinical therapeutics, 2021, Volume: 43, Issue:9 Topics: COVID-19; Double-Blind Method; Humans; Ivermectin; SARS-CoV-2; Treatment Outcome	2021
Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. American journal of therapeutics, 2021, 08-06, Volume: 28, Issue:5 Topics: Antiparasitic Agents; COVID-19; COVID-19 Drug Treatment; Humans; Ivermectin; Randomized Controlled Trials as Topic; Sample Size; SARS-CoV-2	2021
Evidence on the efficacy of ivermectin for COVID-19: another story of apples and oranges. BMJ evidence-based medicine, 2022, Volume: 27, Issue:3 Topics: COVID-19; Humans; Ivermectin	2022
Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-CoV-2: A computational and biophysical approach. Biophysical chemistry, 2021, Volume: 278 Topics: alpha Karyopherins; Animals; Antiviral Agents; beta Karyopherins; Binding Sites; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; DNA Helicases; Humans; Ivermectin; Kinetics; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Protein Interaction Domains and Motifs; SARS-CoV-2; Thermodynamics	2021